All In Biotech

Drug Trial Radar · NCT07658534

A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

A Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Mar 3, 2026

Primary completion

Dec 2028

Study completion Jan 2029

Sponsor

Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Respiratory syncytial virus (RSV) is recognized worldwide as a significant pathogen causing lower respiratory tract infection in infants, the elderly, and immunocompromised patients, which may cause bronchiolitis or pneumonia, and affect the cardiovascular system, central nervous system and the renal system, resulting in hospitalization and death risks in children and also high-risk adults, particularly the elderly. The purpose of this study is to evaluate the efficacy of Ziresovir (AK0529) compared to placebo with respect to the time to resolution of RSV lower respiratory tract disease (LRTD) symptoms.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • Ziresovir (AK0529)Drug

    Active Substance: AK0529 Pharmaceutical Form: Enteric Capsules Route of Administration: Oral

  • PlaceboDrug

    Active Substance: Placebo Pharmaceutical Form: Enteric Capsules Route of Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from first dose to resolution of LRTD symptomsTime frame: Up to Day 27

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Guangzhou Medical University Panyu Central Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Cangzhou Hospital of Integrated TCM-WM

    Cangzhou, Hebei, China · Recruiting

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, China · Recruiting

  • Henan Infectious Disease Hospital (The Sixth People's Hospital of Zhengzhou)

    Zhengzhou, Henan, China · Not yet recruiting

  • Wuhan Sixth Hospital

    Wuhan, Hubei, China · Recruiting

  • Zhejiang Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • People's Hospital of Rui'an City

    Rui’an, Zhejiang, China · Recruiting

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.